# A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

> **NCT01231594** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 214 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** GSK2118436
- **DRUG:** GSK1120212
- **DRUG:** Other approved anti-cancer agent

## Key facts

- **NCT ID:** NCT01231594
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-05
- **Primary completion:** 2018-04-09
- **Final completion:** 2018-04-09
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2019-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01231594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01231594, "A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01231594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*